(SCNX) Scienture Holdings - Ratings and Ratios
Pharmaceutical, Generic, Branded, Injectables, Oral
SCNX EPS (Earnings per Share)
SCNX Revenue
Description: SCNX Scienture Holdings
Scienture Holdings, Inc. (NASDAQ:SCNX) is a pharmaceutical company that focuses on developing and commercializing treatments for central nervous system and cardiovascular diseases. The company operates through two segments: Integra, which handles wholesale and sales of licensed pharmaceutical brands, generics, and non-drug products, and Scienture, which is responsible for researching and developing branded pharmaceutical products.
The companys pipeline includes several promising candidates, such as SCN-102, an oral liquid formulation of losartan potassium for treating hypertension and diabetic nephropathy, currently in Phase 1. Other notable candidates include SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen, SCN-106, a thrombolytic agent, and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical pain management.
Analyzing the technical data, the stocks last price is $0.90, with a 20-day SMA of $0.93 and a 50-day SMA of $1.15, indicating a potential downtrend. The 200-day SMA is $4.97, suggesting a significant long-term decline. The ATR is $0.08, representing a 9.26% volatility. The stock has traded between $0.78 and $20.92 over the past 52 weeks, indicating high volatility.
From a fundamental perspective, Scienture Holdings has a market capitalization of $27.09M USD, with a forward P/E ratio of 21.83, suggesting potential for growth. The companys RoE is 19.13%, indicating relatively strong profitability.
Combining technical and fundamental analysis, a forecast for SCNX can be made. Given the current downtrend and high volatility, a potential trading range could be between $0.80 and $1.20 in the short term. However, if the companys pipeline candidates, particularly SCN-102, show positive results in Phase 1, the stock could experience a significant surge. Long-term investors may consider accumulating positions around the current price, targeting a potential price of $5-7 if the companys products gain FDA approval and achieve commercial success. A stop-loss around $0.70-$0.80 is recommended to limit potential losses.
SCNX Stock Overview
| Market Cap in USD | 18m |
| Sub-Industry | Health Care Technology |
| IPO / Inception | 2010-04-27 |
SCNX Stock Ratings
| Growth Rating | -86.2% |
| Fundamental | 25.3% |
| Dividend Rating | 1.0% |
| Return 12m vs S&P 500 | -89.2% |
| Analyst Rating | - |
SCNX Dividends
Currently no dividends paidSCNX Growth Ratios
| Growth Correlation 3m | 36.6% |
| Growth Correlation 12m | -79.6% |
| Growth Correlation 5y | -83.7% |
| CAGR 5y | -55.42% |
| CAGR/Max DD 5y | -0.56 |
| Sharpe Ratio 12m | -1.88 |
| Alpha | -135.10 |
| Beta | 3.406 |
| Volatility | 106.22% |
| Current Volume | 117.9k |
| Average Volume 20d | 269.1k |
| Stop Loss | 0.9 (-8.2%) |
| Signal | -2.37 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-20.1m TTM) > 0 and > 6% of Revenue (6% = 7692 TTM) |
| FCFTA -0.14 (>2.0%) and ΔFCFTA 1.31pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -5329 % (prev 292.9%; Δ -5622 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.13 (>3.0%) and CFO -13.3m > Net Income -20.1m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.11 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.1m) change vs 12m ago 494.8% (target <= -2.0% for YES) |
| Gross Margin -6.30% (prev 76.77%; Δ -83.07pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.22% (prev 21.25%; Δ -21.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -6.94 (EBITDA TTM -17.7m / Interest Expense TTM 2.56m) >= 6 (WARN >= 3) |
Altman Z'' -5.90
| (A) -0.07 = (Total Current Assets 856.6k - Total Current Liabilities 7.69m) / Total Assets 104.3m |
| (B) -0.47 = Retained Earnings (Balance) -48.8m / Total Assets 104.3m |
| (C) -0.30 = EBIT TTM -17.7m / Avg Total Assets 59.6m |
| (D) -1.85 = Book Value of Equity -48.8m / Total Liabilities 26.4m |
| Total Rating: -5.90 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.27
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -65.87% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 = 2.50 |
| 5. Debt/Ebitda -0.20 = -2.50 |
| 6. ROIC - WACC -38.94% = -12.50 |
| 7. RoE -24.91% = -2.50 |
| 8. Rev. Trend -68.73% = -3.44 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend 23.39% = 0.58 |
| 11. EPS CAGR 21.18% = 2.12 |
What is the price of SCNX shares?
Over the past week, the price has changed by -5.34%, over one month by -50.76%, over three months by +7.60% and over the past year by -87.32%.
Is Scienture Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SCNX is around 0.61 USD . This means that SCNX is currently overvalued and has a potential downside of -37.76%.
Is SCNX a buy, sell or hold?
What are the forecasts/targets for the SCNX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.7 | -24.5% |
Last update: 2025-08-21 11:34
SCNX Fundamental Data Overview
CCE Cash And Equivalents = 15.4k USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 2.1961
P/E Forward = 21.8341
P/S = 140.9256
P/B = 0.232
Beta = None
Revenue TTM = 128.2k USD
EBIT TTM = -17.7m USD
EBITDA TTM = -17.7m USD
Long Term Debt = 1.58m USD (from longTermDebt, last quarter)
Short Term Debt = 2.03m USD (from shortTermDebt, last quarter)
Debt = 3.61m USD (Calculated: Short Term 2.03m + Long Term 1.58m)
Net Debt = 3.59m USD (from netDebt column, last quarter)
Enterprise Value = 21.7m USD (18.1m + Debt 3.61m - CCE 15.4k)
Interest Coverage Ratio = -6.94 (Ebit TTM -17.7m / Interest Expense TTM 2.56m)
FCF Yield = -65.87% (FCF TTM -14.3m / Enterprise Value 21.7m)
FCF Margin = -11.1k% (FCF TTM -14.3m / Revenue TTM 128.2k)
Net Margin = -15.7k% (Net Income TTM -20.1m / Revenue TTM 128.2k)
Gross Margin = -6.30% ((Revenue TTM 128.2k - Cost of Revenue TTM 136.3k) / Revenue TTM)
Tobins Q-Ratio = -0.44 (set to none) (Enterprise Value 21.7m / Book Value Of Equity -48.8m)
Interest Expense / Debt = 18.12% (Interest Expense 653.5k / Debt 3.61m)
Taxrate = 21.0% (US default)
NOPAT = -17.7m (EBIT -17.7m, no tax applied on loss)
Current Ratio = 0.11 (Total Current Assets 856.6k / Total Current Liabilities 7.69m)
Debt / Equity = 0.05 (Debt 3.61m / last Quarter total Stockholder Equity 77.9m)
Debt / EBITDA = -0.20 (Net Debt 3.59m / EBITDA -17.7m)
Debt / FCF = -0.25 (Debt 3.61m / FCF TTM -14.3m)
Total Stockholder Equity = 80.8m (last 4 quarters mean)
RoA = -19.30% (Net Income -20.1m, Total Assets 104.3m )
RoE = -24.91% (Net Income TTM -20.1m / Total Stockholder Equity 80.8m)
RoCE = -21.54% (Ebit -17.7m / (Equity 80.8m + L.T.Debt 1.58m))
RoIC = -21.08% (NOPAT -17.7m / Invested Capital 84.2m)
WACC = 17.86% (E(18.1m)/V(21.7m) * Re(18.57%)) + (D(3.61m)/V(21.7m) * Rd(18.12%) * (1-Tc(0.21)))
Shares Correlation 5-Years: 100.0 | Cagr: 125.8%
Discount Rate = 18.57% (= CAPM, Blume Beta Adj.) -> capped to 17.95% (dynamic)
Fair Price DCF = unknown (Cash Flow -14.3m)
Revenue Correlation: -68.73 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: -72.39
EPS Correlation: 23.39 | EPS CAGR: 21.18%
EPS Growth-of-Growth: -41.15
Additional Sources for SCNX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle